A randomized, open-label, phase 2 study of Botensilimab (AGEN1181) as monotherapy and in combination with Balstilimab (AGEN2034) or investigator's choice standard of care (Regorafenib or Trifluridine and Tipiracil) for the treatment of refractory metastatic colorectal cancer.

MyChart

Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
Request an Appointment

If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information

New Patients Current Patients Referring Physicians
Donate Today